Search results for ''
AASLD 2020
13-16 November, 2020
Digital edition
ENYO Pharma attended the 2020 digital edition of AASLD meeting.
The meeting confirms vonafexor (EYP001, FXRag) unique positioning for HBV and possible differentiated profile for NASH with ph2s on track to deliver in H1 2021.
We also presented a poster describing a novel small molecule modulating the mitochondrial NEET proteins that improves inflammation and fibrosis in liver and kidneys of NASH mice :
American Society of Nephrology – Kidney Week 2020
ENYO Pharma is present at the digital Kidney Week 2020 organized by the ASN with a poster. ASN has been honored to host the world’s premier meeting in nephrology for 50+ years, which has been “Reimagined” as a fully digital meeting.
“A novel small molecule modulating the mitochondrial NEET proteins improves inflammation and fibrosis in kidneys of NASH mice”
Selection for international MATWIN board
Digital meeting
13-14 October, 2020
MATWIN (Maturation & Accelerating Translation within Industry) is an innovation platform that aims to accelerate transfer of oncology innovation from academia & SMEs to clinical development. 13 Pharma partners and numerous academic opinion leaders review proposals for partnership opportunities that offer most promise for patient well being. ENYO Pharma project is selected for a pitch to participating VC investors for start-up funds.
EASL – The Digital International Liver Congress 2020
August 27-29, 2020
Digital congress
ENYO Pharma was connected from the 27th to the 29th of August at the digital EASL International Liver Congress and present 2 posters.
“Characterization of EYP001 a novel, potent and selective FXR agonist in in vitro 3D human liver models”
“A novel small molecule modulating the mitochondrial NEET (CISD) proteins activity improves inflammation and fibrosis in a diet-induced model of non-alcoholic steatohepatitis”
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
Brussels, Belgium – 18 August 2020 – CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totaling € 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and three IMI-Associated Partners.
Latest Press Release 